Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

ing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    USA:    +1-646-240-4193
    Office: +972-2-566-0001
    Email: tara@oramed.com

'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Lionbridge (Nasdaq: LIOX ) today announced ... master services agreement with a multi-billion dollar ... serve patients in approximately 100 countries. With ... provider for translation of the company,s online ... resources, legal, and corporate communications information. Lionbridge ...
(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/14/2009)... , - Results From ... Rheumatoid Arthritis in Seven Major Industrialized Countries , , ... arthritis say their disease, impacts ... Women living with rheumatoid arthritis find shopping for gifts, ... wrapping presents most, difficult to ...
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
Breaking Biology Technology:Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX) ... of AppTec Laboratory,Services, Inc., a US-based service ... AppTec offers testing, contract research and,development, and ... fully integrated platform., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
... PALO ALTO, Calif., Jan. 31 CV Therapeutics,Inc. (Nasdaq: ... an Investor Science,Day for the financial community in New ... a.m. EST., The event will be webcast live ... http://www.cvt.com ., About CV Therapeutics, CV Therapeutics, ...
... Discuss Plans for Company in 2008 and Beyond ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ), announced today ... 7, at 10:00 AM EST. President and,Chief Executive ... business strategy. Emisphere is a biopharmaceutical company that,focuses ...
Other Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3
(Date:12/15/2009)... Springer has just signed an agreement with the British ... an affiliation with the journal Biogerontology for ... will appoint one member of the Biogerontology ... issue annually. Springer will sponsor the society and ... Biogerontology on www.springerlink.com . , Biogerontology ...
(Date:12/15/2009)... ancient American horses may have been grazing the ... than previously thought. After plucking ancient DNA from ... researchers used cutting-edge techniques to uncover "genetic fossils" ... to between 7,600 and 10,500 calendar years. This ... of these now-extinct mammals endured longer in the ...
(Date:12/15/2009)... consumers can look forward to ultra-low powered or ... and mobile phones. This is made possible with ... are critical elements for power optimisation and higher ... Analog IC design is the key enabling capability ... the nation in advanced analog and mixed signal ...
Breaking Biology News(10 mins):Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 1Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 2Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 3Infants Should Be Screened for Hip Trouble 50526 1Infants Should Be Screened for Hip Trouble 50526 2Infants Should Be Screened for Hip Trouble 50526 3Christian Childrens Fund Name Change to ChildFund International Official 50524 1Christian Childrens Fund Name Change to ChildFund International Official 50524 2
... retroviral resistance gene, called FEZ1, that can mediate a potent ... cell culture. The researchers found that the high level of ... a significant block to retroviral infection ?retroviruses were able to ... were excluded from entering the host cell nucleus. , "We ...
... much more canny predators than previously thought, ecologists have ... British Ecological Society's Journal of Animal Ecology, basking sharks ... at dawn and surfacing at dusk in order to ... As well as shedding new light on basking behaviour, ...
... the abnormal repetition of a genetic sequence can have ... that govern balance and motor coordination. The studies bolster ... by having extra copies of a normal protein, not ... with the rare neurodegenerative disorder spinocerebellar ataxia type 1 ...
Other Biology News:Plankton can run, but can't hide from basking sharks 2Pinpointing the cause of a neurodegenerative disorder 2Pinpointing the cause of a neurodegenerative disorder 3
... the standard water based mounting medium for ... permanent preservation of peroxidase and alkaline phosphatase ... use and exhibits excellent optical characteristics. Crystal ... medium that permits the long-term storage of ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Request Info...
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
Biology Products: